GU Oncology Now Journal

Read the Issue

The Effect of Robot-assisted Radical Cystectomy in Bladder Cancer: A Review

There has been significant controversy over the adoption of robotic surgery for cystectomy with intracorporeal diversion over the traditional open radical approach. In a...

Safety of Relugolix in Advanced Prostate Cancer–Analysis from the HERO Trial

In this moderated poster presentation at the American Urological Association (AUA) 2022 meeting, Neal Shore, MD, detailed the safety analysis of the phase 3...

The Latest Updates in PSMA Diagnostics and Theranostics From AUA 2022

At the American Urological Association (AUA) 2022 meeting in New Orleans, the Friday plenary session consisted of several high-yield discussions. One important topic covered by...

Debating Single Versus Multiport Robotic Prostatectomy

At the American Urological Association (AUA) 2022 meeting in New Orleans, one of the highlights of the plenary session was a debate between Jeffrey...

Health Equity: Women and Underrepresentation in Urologic Oncology

At the American Urological Association (AUA) 2022 meeting in New Orleans, Eila C. Skinner, MD, of Stanford Health Care, chaired the presentation on women...

Focal Therapy for Prostate Cancer: Should it Become a Standard of...

Where has focal therapy found its place in the treatment for prostate cancer? This was discussed at the American Urological Association (AUA) 2022 meeting...

Editor’s Talk: Triplet Versus Doublet Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Daniel Tennenbaum, MD Although most cases of prostate cancer present at an early stage, and often with an indolent course, the disease continues to be...

Profiles in GU Oncology: Brian M. Shuch, MD

Brian M. Shuch, MD, describes his career path through 20 years, working with several leading urologists as mentors during his training. When Dr Brian Shuch...

Episode 161: Platinum Ineligibility in Urothelial Cancer

Linda Brookes, MSc Although cisplatin-based combination chemotherapy is still considered first-line standard of care in metastatic urothelial carcinoma (mUC), many patients are deemed ineligible for...

Read the Issue

Profiles in GU Oncology: Heather H. Cheng, MD, PhD

HEATHER H. CHENG, MD, PHD is an Associate Professor in the Department of Medicine, Division of Medical Oncology, University of Washington (UW); Associate Professor,...

Thermal Ablation for Small Renal Masses

Nearly 80,000 patients in the United States will be diagnosed with kidney cancer in 2022.1 Of these patients, an estimated 13,920 will experience kidney...

Practicing Mindfulness in Surgery: A Discussion with Phillip Pierorazio, MD, Creator...

Phillip Pierorazio, MD, is the chief of urology at Penn Presbyterian Medical Center and a professor of surgery at the Hospital of the University...

Exclusive Interview: Nazli Dizman, MD on RCC Immunotherapy with Gut Microbiome...

In April 2022, we highlighted a novel phase 1 clinical trial published in Nature Medicine by Dizman and colleagues.1 In that trial, the authors...

Investigating Racial Disparities in MRI-Fusion Biopsy Utilization in the Assessment of...

It has been well-documented that, compared with their White counterparts, African American men have higher rates of prostate cancer (PCa) diagnoses, often present with...

Improving Enrollment for Prostate Cancer Clinical Trials

Patients who participate in oncology clinical trials have better outcomes than nonparticipants, and the results of such trials are ultimately used to guide treatment...

What Providers Should Know About Trimodal Therapy for Bladder Cancer

The American Cancer Society (ACS) estimates that in 2022, close to 81,000 new cases of bladder cancer will be diagnosed, and nearly 17,000 patients...

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Is there more on the horizon for the treatment of patients with metastatic prostate cancer? According to research recently published in the New England...

Episode 159: NeoAvAx – Expanding the Understanding of Neoadjuvant Therapy in...

Linda Brookes, MSc Patients with localized, high-risk clear cell renal cell carcinoma (ccRCC) experience recurrence rates of over 60%.1 Clinical trials in these patients have...

Read the Issue

Breaking the Boundaries Between Radiology and Oncology: GU Oncology Profiles Thomas...

Thomas A. Hope, MD, Associate Professor, Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging, University of California, San Francisco (UCSF),...

Oncologist’s View: Germline Testing in Prostate Cancer

Germline testing has become increasingly common for men with prostate cancer since the discovery that many men with advanced disease carry germline alterations in...

History and Clinical Applications of PARP Inhibitor Therapy for Prostate Cancer

Poly (ADP-ribose) polymerase, also known as PARP, is a family of proteins described as early as the 1980s to be involved in repair pathways...

Augmenting Metastatic RCC Immunotherapy with Gut Microbiome Modulation

A recently published study in Nature Medicine by Nazli Dizman and colleagues1 reports on a preliminary phase 1 clinical trial offering promising early results...

Disparities in Delivering Targeted Therapies for Prostate Cancer in African American...

Current disparities in the treatment of prostate cancer with targeted therapies across the US— and ways in which this might be affected by advanced...

Strategies for Improving Erectile Function Recovery After Radical Prostatectomy

Approaches aimed at improving outcomes in the treatment of erectile dysfunction among men undergoing radical prostatectomy (RP) are reviewed in the March 2022 issue...

Adjuvant Pembrolizumab After Nephrectomy for Renal Cell Carcinoma

In the era of immunotherapy, it is unfortunate that patients with higher risk renal cell carcinoma (RCC) have limited adjuvant therapeutic options. According to...

Episode 155: ASCO GU 2022 ARASENS trial of darolutamide and chemo...

Over the past decade, the gold-standard treatment for metastatic hormone-sensitive prostate cancer (mHSPC) has evolved from single-agent androgen deprivation therapy (ADT) to the addition...

Read the Issue

Read the Issue

Read the Issue

Curated Journal reading List